Skip to content. | Skip to navigation

Personal tools


Managing bodies

logo Inserm      logo cnrslogo ENSL       logo ucb1

Secondary managing bodies

logo ENSL logo ucb1

You are here: Home / Teams / Henry T - I2BA / Research projects / Deregulation of inflammasomes in autoinflammatory diseases

Deregulation of inflammasomes in autoinflammatory diseases

Inflammasomes are highly regulated innate immune platforms. When this regulation is unbalanced it can lead to autoinflammatory diseases termed inflammasomopathies.Enter in our bench to bedside research theme led by Yvan Jamilloux!

Inflammasomopathies can be classified in two groups: monogenic inflammasomopathies and complex inflammasomopathies.

Monogenic inflammasomopathies are due to mutations in inflammasome genes. Our main focus is on Familial Mediterraean Fever (FMF), an autoinflammatory disease associated with mutation in the MEFV gene encoding Pyrin, an inflammasome sensor.

We discovered that FMF-associated MEFV mutations decrease the threshold of activation of the pyrin inflammasome providing a first clue of why FMF patients suffer from recurrent episodes of inflammation. Full story here!

We then looked into the mechanistics of pyrin inflammasome in healthy donors and FMF patients to uncover the deregulation mechanisms. We discovered that the pyrin inflammasome is controlled by two mechanisms, one of it deficient in FMF patients. The full article by Flora Magnotti and her colleagues!

This work also highlighted that there is still a lot to learn on the pyrin inflammasome and its regulation both at steady state and during inflammation.


Studying rare monogenic diseases is important for patients suffering from these diseases but is also important to learn about complex inflammasomopathies. We are thus using our inflammasome expertise to investigate the deregulation of inflammation in several complex autoinflammatory diseases, including Still's disease. This work is largely based on immunophenotyping of primary human cells and is supported by European Union’s Horizon 2020 research and innovation programme. See ImmunAID project!